证券代码：300110 证券简称：华仁药业 公告编号：2025-057 华仁药业股份有限公司 2025 年第一次临时股东会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载，误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情况； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开及召集情况 1、会议通知情况：华仁药业股份有限公司（以下简称"公司"）2025年8月16 日以董事会公告方式向全体股东发出召开2025年第一次临时股东会的通知。 2、会议召开时间： （1）现场会议召开时间：2025年9月1日14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年9月1日上午9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025年9月1日上午9:15-下午15:00 期间的任意时间。 3、会议召开地点：山东省青岛市高科技工业园株洲路187号公司会议室。 4、会议召集人：公司董事会。 5、会议召开方式：采取现场投票与网络投票相结合的方式。 6、 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-058 地址：合肥市包河工业区纬五路 15 号 华仁药业股份有限公司 关于全资子公司盐酸奈福泮原料药获得上市申请批准 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸奈福泮"《化学原料药上市申请批准通知书》（通知书编号：2025YS00762）。 现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸奈福泮 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 二、药品的其他情况 盐酸奈福泮为非麻醉性、非成瘾性强力镇痛药，兼有轻度的解热和肌松作用， 临床主要对症治疗急性疼痛，尤其是术后疼痛，亦可作为局部麻醉、针麻等麻醉 辅助用药。盐酸奈福泮不属于精神类镇痛药，不存在成瘾性；多年的临床实践亦 2．英文名 ...

Group 1 - The core viewpoint of the news is that Huaren Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and operational performance [1][2]. - On August 29, Huaren Pharmaceutical's stock fell by 2.06%, with a trading volume of 97.32 million yuan. The financing buy-in amount was 10.06 million yuan, while the net financing buy-in was 3.41 million yuan, indicating a relatively high financing balance of 237 million yuan, which accounts for 6.03% of the circulating market value [1]. - The company's main business revenue composition includes: basic infusion (40.63%), peritoneal dialysis fluid (34.90%), therapeutic preparations (14.92%), medical devices (8.14%), and others (1.41%) [1]. Group 2 - As of August 20, the number of shareholders of Huaren Pharmaceutical was 41,000, a decrease of 1.20% from the previous period, while the average circulating shares per person increased by 1.22% to 28,801 shares [2]. - For the first half of 2025, Huaren Pharmaceutical reported an operating income of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to the parent company of 37.33 million yuan, down 49.01% year-on-year [2]. - The company has distributed a total of 294 million yuan in dividends since its A-share listing, with cumulative distributions of 49.65 million yuan over the past three years [3].

Core Viewpoint - Hua Ren Pharmaceutical experienced a decline of 4.96% in stock price on August 27, with a trading volume of 174 million yuan, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Financing Summary - On August 27, Hua Ren Pharmaceutical had a financing buy-in amount of 20.02 million yuan and a financing repayment of 20.01 million yuan, resulting in a net financing buy of -1,262 yuan [1]. - The total financing and securities balance for Hua Ren Pharmaceutical as of August 27 was 240 million yuan, which accounts for 5.88% of its circulating market value, indicating a relatively high level compared to the past year [1]. - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1]. Business Performance - As of August 20, the number of shareholders for Hua Ren Pharmaceutical was 41,000, a decrease of 1.20% from the previous period, while the average circulating shares per person increased by 1.22% to 28,801 shares [2]. - For the first half of 2025, Hua Ren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Dividend Information - Since its A-share listing, Hua Ren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3].

Core Viewpoint - Huarun Pharmaceutical is facing significant challenges, including a leadership change and its first loss since going public, primarily due to receivables and goodwill impairment [2][5][6]. Company Overview - Huarun Pharmaceutical was established in May 1998, focusing on the production and sales of narcotic injections, basic and therapeutic large-volume preparations, and medical devices [2]. - The company has been listed on the Shenzhen Stock Exchange's Growth Enterprise Market since 2010 [5]. Leadership Change - Chairman Zhang Li has been placed under residential surveillance and has resigned from his position after less than four months in office [2][3]. - The board has appointed director Hou Ruipeng to act as the chairman and legal representative temporarily [4]. Financial Performance - In 2024, the company reported a revenue of 1.353 billion yuan, a year-on-year decline of 17.30%, and a net loss attributable to shareholders of 1.368 billion yuan, a staggering drop of 827.67% [6]. - The company is experiencing its first loss since its IPO, attributed to receivables and goodwill impairment [5][6]. Receivables and Impairment Issues - Huarun Pharmaceutical's subsidiary, Qingdao Huarun Pharmaceutical Co., has a net receivable of approximately 1.348 billion yuan from China National Pharmaceutical Group, leading to a full credit impairment provision [7]. - The company plans to negotiate with China National Pharmaceutical Group regarding the collection of outstanding debts [7]. Sales and Revenue Decline - The overall sales volume of the company's products decreased by 9.46% in 2024, with self-produced drug revenue dropping by 9.43% [8]. - Despite growth in key products like peritoneal dialysis fluid and therapeutic preparations, their revenue contribution remains significantly lower than that of basic infusion products [8]. Recent Performance Trends - In the first half of 2025, the company continued to struggle, reporting a revenue of 624 million yuan, down 19.13%, and a net profit of 37.33 million yuan, a decline of 49.01% [9]. - The company's self-produced drug revenue for the reporting period was 564 million yuan, reflecting an 18.90% year-on-year decrease [11].

Core Viewpoint - Huarun Pharmaceutical (300110.SZ) faces significant financial challenges due to a large outstanding debt from Guoyao Pharmaceutical, leading to substantial losses and management changes [2][3][5]. Company Overview - Huarun Pharmaceutical is a state-controlled pharmaceutical and health company headquartered in Qingdao, Shandong, with its actual controller being the Xi'an Qujiang New District Management Committee [2]. - The company primarily produces basic infusion solutions, peritoneal dialysis solutions, therapeutic preparations, medical devices, and others [2]. Management Changes - On August 26, 2023, Huarun Pharmaceutical announced that its chairman, Zhang Li, was placed under residential surveillance by the police, unrelated to the company or its business [2]. - Zhang Li resigned from his positions as chairman and legal representative after only four months in office, having taken over from Yang Xiaodong, who resigned in April 2023 [2]. Financial Performance - In the first half of 2025, Huarun Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37 million yuan, down 49.01% [2]. - The decline in revenue is attributed to intensified market competition in infusion products and the impact of drug pricing policies [2]. Debt Issues - Huarun Pharmaceutical has an outstanding debt of nearly 1.3 billion yuan owed by Guoyao Pharmaceutical, which has been difficult to recover [2][5]. - The company reported a loss of nearly 1.3 billion yuan in its pharmaceutical distribution business, which is not its core operation [2][3]. Other Receivables - As of December 31, 2023, Huarun Pharmaceutical had other receivables totaling 1.41 billion yuan, with 96.06% of this amount being related to a single advance payment, for which a bad debt provision of 70 million yuan was made [3][5]. - The company has been in discussions with Guoyao Pharmaceutical regarding repayment, but the latter is facing liquidity issues and operational irregularities [5][7]. Legal and Operational Issues - Guoyao Pharmaceutical has been involved in multiple lawsuits and has been listed as a party subject to enforcement, raising concerns about its ability to repay debts [5][6]. - The company has faced scrutiny for its operational practices, including allegations of trademark infringement and fraudulent activities [5]. Future Outlook - Huarun Pharmaceutical plans to continue negotiations with Guoyao Pharmaceutical to recover the outstanding debts and has proposed a debt resolution framework involving asset compensation [7]. - The ability to recover these debts is a significant concern for investors, with ongoing inquiries about the company's plans and progress in this regard [7].

Group 1 - Aofei Data achieved a net profit of 87.89 million yuan in the first half of 2025, a year-on-year increase of 16.09% [1] - Aofei Data's revenue for the same period was 1.148 billion yuan, up 8.20% year-on-year [1] - The company specializes in IDC services, internet business, system integration, and distributed photovoltaic energy-saving services [1] Group 2 - Meilan De reported a net profit of 63.92 million yuan, a year-on-year decrease of 11.96% [1] - The company's revenue was 241 million yuan, reflecting a growth of 5.62% year-on-year [1] - Meilan De focuses on the research, production, sales, and service of medical devices related to pelvic and obstetric rehabilitation [1] Group 3 - Jiuan Medical posted a net profit of 920 million yuan, a significant year-on-year increase of 52.91% [1] - The company's revenue decreased by 43.35% to 765 million yuan [1] - Jiuan Medical specializes in the research, production, and sales of home medical devices [2] Group 4 - Hanbang Technology's net profit fell by 26.24% to 27.80 million yuan [2] - The company achieved a revenue of 349 million yuan, a growth of 5.99% year-on-year [2] - Hanbang Technology provides professional separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [2] Group 5 - Jinjing Environment reported a net profit of 78.69 million yuan, a year-on-year increase of 13.73% [2] - The company's revenue was 782 million yuan, reflecting a growth of 1.70% [2] - Jinjing Environment focuses on investment operation management services and equipment manufacturing in the environmental sanitation sector [2] Group 6 - Tianbao Infrastructure achieved a net profit of 118 million yuan, a remarkable year-on-year increase of 2106.58% [3] - The company's revenue decreased by 8.31% to 486 million yuan [3] - Tianbao Infrastructure is involved in real estate development, property leasing, and management [4] Group 7 - Weihuaxin Materials reported a net profit of 83.15 million yuan, a year-on-year decrease of 52.91% [5] - The company's revenue was 437 million yuan, down 30.71% year-on-year [5] - Weihuaxin Materials specializes in the research and production of chlorotoluene and trifluoromethylbenzene products [5] Group 8 - Tianchen Medical posted a net profit of 48.21 million yuan, a year-on-year increase of 67.10% [6] - The company's revenue was 156 million yuan, reflecting a growth of 17.66% [6] - Tianchen Medical focuses on the research, innovation, and production of high-end surgical staplers [6] Group 9 - Greenland Holdings reported a net loss of 3.506 billion yuan in the first half of 2025 [8] - The company's revenue was 9.45 billion yuan, down 18.06% year-on-year [8] - Greenland Holdings is involved in various financial services including securities, futures, and trust [8] Group 10 - Wukuang Capital's net profit decreased by 41.47% to 525 million yuan [9] - The company achieved a total revenue of 623 million yuan, a significant increase of 144.86% [9] - Wukuang Capital operates in the financial sector, providing services such as securities and leasing [9] Group 11 - Yutong Technology reported a net profit of 554 million yuan, a year-on-year increase of 11.42% [10] - The company's revenue was 7.876 billion yuan, reflecting a growth of 7.10% [10] - Yutong Technology specializes in the research, design, production, and sales of paper packaging products [10] Group 12 - Wewei Co. posted a net profit of 120 million yuan, a year-on-year decrease of 20.14% [11] - The company's revenue was 1.521 billion yuan, down 12.76% year-on-year [11] - Wewei Co. focuses on the production and sales of various food and beverage products [11] Group 13 - Tongfang Co. reported a net loss of 256 million yuan in the first half of 2025 [12] - The company's revenue was 5.667 billion yuan, down 10.09% year-on-year [12] - Tongfang Co. is engaged in the development of smart technology and nuclear technology applications [12] Group 14 - Liugang Co. achieved a net profit of 368 million yuan, a year-on-year increase of 579.54% [13] - The company's revenue was 34.675 billion yuan, down 8.32% [13] - Liugang Co. specializes in coke, sintering, iron, steel smelting, and steel processing [13] Group 15 - China National Petroleum Corporation reported a net profit of 83.993 billion yuan, with a proposed dividend of 0.22 yuan per share [14] - The company's revenue was 1.45 trillion yuan, down 6.7% year-on-year [14] - The company is involved in oil and gas exploration, production, refining, and sales [14] Group 16 - Fangda Carbon's net profit decreased by 68.31% to 54.53 million yuan [15] - The company's revenue was 1.690 billion yuan, down 28.13% year-on-year [15] - Fangda Carbon specializes in the research, production, and sales of graphite and carbon materials [15] Group 17 - Xinmai Medical reported a net profit of 31.5 million yuan, a year-on-year decrease of 22.03% [18] - The company's revenue was 714 million yuan, down 9.24% year-on-year [18] - Xinmai Medical focuses on the research, production, and sales of vascular intervention medical devices [18] Group 18 - Hengbao Co. posted a net profit of 35.35 million yuan, a year-on-year decrease of 44.41% [19] - The company's revenue was 430 million yuan, down 8.64% year-on-year [19] - Hengbao Co. specializes in high-end intelligent products and digital security solutions [19] Group 19 - Zhongji Xuchuang reported a net profit of 3.995 billion yuan, a year-on-year increase of 69.40% [20] - The company's revenue was 14.789 billion yuan, reflecting a growth of 36.95% [20] - Zhongji Xuchuang specializes in high-end optical communication modules and devices [20] Group 20 - Guangxian Media achieved a net profit of 2.229 billion yuan, a year-on-year increase of 371.55% [21] - The company's revenue was 3.242 billion yuan, up 143.00% year-on-year [21] - Guangxian Media focuses on investment, production, and distribution of film projects [21] Group 21 - Huarun Pharmaceutical reported a net profit of 37.33 million yuan, a year-on-year decrease of 49.01% [23] - The company's revenue was 624 million yuan, down 19.13% year-on-year [23] - Huarun Pharmaceutical specializes in pharmaceuticals, medical devices, and health products [23] Group 22 - Huawai Technology posted a net profit of 12.7 million yuan, a year-on-year increase of 56.18% [24] - The company's revenue was 937 million yuan, reflecting a growth of 32.62% [24] - Huawai Technology focuses on the research, production, and sales of high-end elastic components [24]

Core Viewpoint - Huarun Pharmaceutical announced that its chairman, Zhang Li, has been placed under residential surveillance by the local police, which is unrelated to the company or its operations. Zhang has submitted his resignation from all positions within the company due to personal reasons [1][4]. Company Management Changes - The board of Huarun Pharmaceutical held a meeting on August 24, 2023, and appointed director Hou Ruipeng to act as chairman and legal representative temporarily. The company will expedite the process of electing a new chairman according to legal procedures [4]. - Zhang Li was elected as the new chairman on April 29, 2023, and his tenure lasted less than four months before the surveillance incident [4][5]. Financial Performance - Huarun Pharmaceutical reported a significant financial downturn in its 2024 annual report, with revenue of 1.353 billion yuan, a year-on-year decrease of 17.3%. The net profit attributable to shareholders was a loss of 1.368 billion yuan, a staggering decline of 827.67% [11]. - The company attributed the massive loss primarily to a full provision for credit impairment losses related to 1.3478 billion yuan owed to China National Pharmaceutical Group [11]. - The company also reported a decline in its 2025 semi-annual results, with revenue of 624 million yuan, down 19.13%, and a net profit of 37.33 million yuan, down 49.01% [12]. Stock Market Performance - As of August 26, 2023, Huarun Pharmaceutical's stock closed at 3.63 yuan per share, with a total market capitalization of 4.291 billion yuan [13].

Core Viewpoint - The recent developments at Huaren Pharmaceutical, including the resignation of Chairman Zhang Li and his subsequent house arrest, raise concerns about the company's governance and financial health, especially following a significant financial loss in 2024 [2][3][15]. Group 1: Leadership Changes - Zhang Li has been placed under house arrest by the local police, which is unrelated to the company or its operations [2]. - Following this, Zhang Li submitted his resignation from all positions within the company, including Chairman and legal representative [3]. - The board of directors has appointed Hou Ruipeng to act as the interim Chairman and legal representative while the company initiates the process for a formal election [5]. Group 2: Financial Performance - Huaren Pharmaceutical reported a revenue of 1.353 billion yuan in 2024, a decrease of 17.3% year-on-year [15]. - The company experienced a net loss of 1.368 billion yuan, marking a staggering decline of 827.67% compared to the previous year [15]. - The significant losses were attributed to a full provision for credit impairment losses related to a debt of 1.3478 billion yuan owed to Guoyao Medicine [16]. Group 3: Historical Context - Zhang Li was appointed as Chairman on April 29, 2025, just months before his current legal troubles [6]. - The company has faced severe financial difficulties, erasing over a decade's worth of accumulated profits and resulting in a net loss exceeding 150 million yuan [15]. - The previous Chairman, Yang Xiaodong, also resigned shortly after the financial report was released, indicating potential instability in leadership [16].

Group 1 - The chairman of Huarun Pharmaceutical, Zhang Li, has resigned due to personal reasons, and this matter is unrelated to the company or its operations [1][3] - The company has appointed director Hou Ruipeng to act as the chairman and legal representative temporarily, and will proceed with the formal election process for a new chairman [1][3] - Zhang Li was appointed as chairman on April 29, 2023, and his tenure lasted less than four months [3] Group 2 - Huarun Pharmaceutical reported a revenue of 624 million yuan for the first half of 2025, a year-on-year decrease of 19.1%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.0% year-on-year [3][4] - The decline in revenue and gross profit is attributed to medical insurance cost control and price reductions due to national and local procurement policies [3] - Despite an overall decline in sales volume, key products such as peritoneal dialysis fluid and blood filtration replacement fluid showed steady growth, with peritoneal dialysis fluid sales increasing by 45.80% year-on-year [4] Group 3 - On August 26, 2023, Huarun Pharmaceutical's stock rose by 0.83%, closing at 3.63 yuan per share, with a total market capitalization of 4.291 billion yuan [5][6]